Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Dec 26, 2019
Amneal Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
Dec 16, 2019
Amneal Appoints Jeff George, John Kiely and Shlomo Yanai to Board of Directors
Dec 12, 2019
Amneal Receives Abbreviated New Drug Application Approval for EluRyng™, the First Generic NuvaRing®
Dec 10, 2019
Amneal to Acquire Majority Interest in AvKARE, Enhancing Access to Growing Federal Healthcare Market
Dec 03, 2019
Amneal Announces the Approval and Launch of Generic Carafate®
Dec 02, 2019
Amneal Announces the Approval and Launch of Generic Revatio® for Oral Suspension and Generic Amicar® Tablets
Nov 26, 2019
Amneal Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference
Nov 22, 2019
UPDATE – Revised Listing of NDC and Lot Numbers to be Recalled
Nov 06, 2019
Amneal Reports Third Quarter 2019 Financial Results
Nov 06, 2019
Amneal Enters into a Licensing Agreement with Kashiv BioSciences, LLC to Develop and Commercialize K127 for the Treatment of Myasthenia Gravis
Oct 10, 2019
Amneal Announces Launch of Generic Invega®
Oct 09, 2019
Amneal to Report Third Quarter 2019 Results on November 6, 2019
Sep 05, 2019
Amneal Announces Approval of Generic Version of Amicar®
Sep 03, 2019
Amneal Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
Aug 05, 2019
Amneal Reports Second Quarter 2019 Financial Results
Aug 05, 2019
Amneal Pharmaceuticals Co-Founders Chirag Patel and Chintu Patel Return as Co-Chief Executive Officers
Jul 22, 2019
Amneal Announces Launch of Generic Lyrica®
Jul 10, 2019
Amneal Pharmaceuticals Announces Restructuring and Costs Savings Plan to Improve Operations and Position the Company for Future Growth
Jul 09, 2019
Amneal to Report Second Quarter 2019 Results on August 8, 2019
Jun 06, 2019
Amneal Pharmaceuticals to Present at Upcoming Investor Conferences
May 15, 2019
Amneal Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference
May 09, 2019
Amneal Reports First Quarter 2019 Financial Results
Apr 08, 2019
Amneal to Report First Quarter 2019 Results on May 9, 2019
Apr 02, 2019
Amneal Names Pradeep Bhadauria as Chief Scientific Officer
Apr 01, 2019
Amneal Announces Agreement with Zentiva to Divest Creo Pharma
Mar 12, 2019
Amneal Announces Launch of Rivastigmine Transdermal System
Mar 06, 2019
Amneal Pharmaceuticals to Present at the Barclays Global Healthcare Conference
Feb 28, 2019
Amneal Reports Fourth Quarter And Full Year 2018 Financial Results
Jan 24, 2019
Amneal to Report Fourth Quarter and Full Year 2018 Results on February 28, 2019
Jan 22, 2019
Amneal Names Accomplished Finance Executive Todd P. Branning As Chief Financial Officer
Jan 14, 2019
Amneal Announces Approval of Rivastigmine Transdermal System
Jan 04, 2019
Amneal Names David A. Buchen Senior Vice President, Chief Legal Officer And Corporate Secretary

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.86.0.1 (opens in new window)
Back to top